Ritlecitinib is a small molecule drug that functions as a selective inhibitor of Janus kinase (JAK) enzymes, specifically targeting JAK1 and JAK3. This compound is primarily investigated for its therapeutic potential in treating autoimmune diseases, particularly rheumatoid arthritis and alopecia areata. Ritlecitinib's mechanism of action involves modulating the immune response by inhibiting the signaling pathways that contribute to inflammation and immune dysregulation. The substance is characterized by its ability to penetrate tissues effectively, which is crucial for its efficacy in targeting systemic conditions. In terms of pharmacokinetics, Ritlecitinib exhibits a favorable absorption profile, with a half-life that supports once-daily dosing. Safety and tolerability profiles are essential considerations in its clinical development, as with any JAK inhibitor, due to potential side effects such as increased risk of infections or changes in blood parameters. Ongoing clinical trials continue to evaluate its effectiveness and safety in various patient populations, contributing to the understanding of its role in modern therapeutic regimens.

Ritlecitinib

1792180-81-4: 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

2-Propen-1-one, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-

Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.

CAS 1792180-81-4: Ritlecitinib

2-Propen-1-one, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-

Ref: IN-DA0026UL

Ritlecitinib

Ref: 54-BUP15365

Ritlecitinib

Ref: TM-T5382

PF 06651600

Ref: 3D-BP168506

Ritlecitinib

Ref: 4Z-R-170001

Ritlecitinib

Ref: TR-R299810